Last10K.com

Protagenic Therapeutics, Inc.New (PTIX) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Protagenic Therapeutics, Inc.New

CIK: 1106565 Ticker: PTIX
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2017
Mar. 30, 2018
Jun. 30, 2017
Document And Entity Information   
Entity Registrant NameProtagenic Therapeutics, Inc.\new  
Entity Central Index Key0001022899  
Document Type10-K  
Document Period End DateDec. 31, 2017  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Entity a Well-known Seasoned IssuerNo  
Entity a Voluntary FilerNo  
Entity's Reporting Status CurrentYes  
Entity Filer CategorySmaller Reporting Company  
Entity Public Float  $ 15,230,814
Entity Common Stock, Shares Outstanding 10,261,419 
Trading SymbolPTIX  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2017  

View differences made from one year to another to evaluate Protagenic Therapeutics, Inc.New's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Protagenic Therapeutics, Inc.New.

Continue

Assess how Protagenic Therapeutics, Inc.New's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Protagenic Therapeutics, Inc.New's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Stockholders' Equity (deficit)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (tables)
Accounts Payable And Accrued Expenses - Schedule Of Accounts Payable And Accrued Expenses (details)
Collaborative Agreements
Collaborative Agreements (details Narrative)
Commitments And Contingencies
Commitments And Contingencies (details Narrative)
Derivative Liabilities
Derivative Liabilities (details Narrative)
Going Concern
Going Concern (details Narrative)
Income Tax (details Narrative)
Income Tax - Schedule Of Deferred Tax Assets And Liabilities (details)
Income Tax - Schedule Of Effective Income Tax Rate Reconciliation (details)
Income Tax - Schedule Of Income Before Income Tax, Domestic And Foreign (details)
Income Taxes
Income Taxes (tables)
Licensing Agreements
Licensing Agreements (details Narrative)
Organization And Nature Of Business
Organization And Nature Of Business (details Narrative)
Stockholders' Equity (deficit)
Stockholders' Equity (deficit) - Summary Of Warrant Issuances (details)
Stockholders' Equity (deficit) (details Narrative)
Stockholders' Equity (deficit) (tables)
Stockholders' Equity (deficit) - Schedule Of Share-based Compensation Nonvested Shares (details)
Stockholders' Equity (deficit) - Schedule Of Share-based Compensation, Stock Options, Activity (details)
Stockholders' Equity (deficit) - Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions (details)
Subsequent Events
Subsequent Events (details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details Narrative)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (details)
Summary Of Significant Accounting Policies - Schedule Of Business Acquisitions, By Acquisition (details)
Summary Of Significant Accounting Policies - Schedule Of Business Acquisitions, By Acquisition (details) (parenthetical)
Summary Of Significant Accounting Policies - Schedule Of Fair Value Measurements, Recurring And Nonrecurring, Valuation Techniques (details)
Summary Of Significant Accounting Policies - Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis (details)
Summary Of Significant Accounting Policies - Schedule Of Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation (details)

Material Contracts, Statements, Certifications & more

Protagenic Therapeutics, Inc.New provided additional information to their SEC Filing as exhibits

Ticker: PTIX
CIK: 1022899
Form Type: 10-K Annual Report
Accession Number: 0001493152-18-004567
Submitted to the SEC: Mon Apr 02 2018 5:31:47 PM EST
Accepted by the SEC: Mon Apr 02 2018
Period: Sunday, December 31, 2017
Industry: Business Services

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/ptix/0001493152-18-004567.htm